The Male Default: How Medical Research Fails Women

For decades, medical researchers favored the male body for its perceived convenience, avoiding the complexities of hormonal fluctuations and pregnancy. This preference created a foundational knowledge gap that now ripples through the entire healthcare system. When clinical trials exclude women, the resulting diagnostic criteria, drug dosages, and treatment guidelines are built on incomplete data.

This "male default" proves costly in practice. Cardiovascular disease remains the leading cause of death for women in the EU, yet they are twice as likely to have heart failure misdiagnosed because their symptoms deviate from male-centric models. Similarly, conditions like endometriosis often languish for up to ten years before diagnosis, frequently dismissed as standard menstrual pain. The cycle is further reinforced by funding: in 2020, only five percent of global research and development capital was directed toward women’s health.

Closing these gaps requires a fundamental shift in how Europe approaches scientific inquiry. Mandating sex and gender-based analysis in all research and ensuring EU-funded projects provide granular, sex-disaggregated data are essential first steps. Beyond the clear moral imperative, there is a massive economic incentive; the World Economic Forum projects that bridging these investment gaps could add $1 trillion to the global economy by 2040. True medical leadership demands that half the population is no longer treated as a statistical variation.